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INTRODUCTION

P r o l i f e r a t i v e v i t r e o r e t i n o p a t h y ( P VR
is the most common cause of failed retinal detachment (RD) surgery, with an incidence of 5%-10% [1] . During the PVR process, the formation of fibrotic membranes within the subretinal, retinal surface, and intravitreal space could lead to failed retinal reattachment [2] . The pathogenesis of fibrotic membranes is characterized by excessive proliferation and retinal migration of cells, such as retinal pigment epithelium (RPE) cells, macrophages and glial cells [3] . The primary cellular change in fibrotic membranes is transdifferentiation from RPE cells to myofibroblasts through epithelial-mesenchymal transition (EMT) [4] . Many in vitro experiments have focused on individual cytokines, and demonstrated their inhibitory effects on EMT. However, the individual effect of these cytokines in vivo experiment were rarely reported. This indicates that PVR is a complicated process involving multiple cytokines and pathways, and that simply inhibiting one factor or pathway may cause compensatory responses in the body. The multifunctional serine/threonine kinase glycogen synthase kinase 3β (GSK3β) is involved in multiple signaling pathways and pathophysiological processes, such as EMT, differentiation, motility, inflammation, proliferation, and metabolism [5] [6] . GSK3β participates in the suppression of a variety of diseases, including cancer, Alzheimer's disease, and diabetes [7] [8] . The functional activity of GSK3β will be activated due to the inhibitation of PI3K [wortmannin (WOR)] [9] . Nevertheless, the mechanism of GSK3β action in EMT has not been fully elucidated. In addition, most previous studies of the pathological mechanism of EMT induced by PVR have focused solely on protein levels, without in vivo analysis of metabolites, which are the end products of biological fluids, cells, or tissues.
Their levels represent a comprehensive response to biological systems or environmental changes, and can be used as potential biomarkers in a number of pathological diseases [10] . Therefore, we have investigated the role of GSK3β in EMT with metabolomic analysis in vivo experiment.
SUBJECTS AND METHODS
Animals and Proliferative Vitreoretinopathy Induction
Adult New Zealand white rabbits (72 in total; 2.0-2.5 kg) were obtained from the Shanghai Laboratory Animal Center at the Chinese Academy of Sciences, and maintained in a 12h light/dark cycle. Food and water were supplied ad libitum. All animal experiments in this study conformed to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Briefly, after 1wk of accommodation, PVR was induced by intravitreal injection of 1.0 × 10 6 human ARPE19 cells in 0.1 mL buffered salt solution (BSS) with a 30-gauge needle (after anterior chamber paracentesis) as previously described [11] .
Drug Injection and Observation
We randomly selected 42 rabbits, whose right eyes were injected with 0.3 mmol/L WOR (Selleckchem 52758; Houston, TX, USA), a phosphoinositol-3 kinase (PI3K) inhibitor. They were further randomly separated into equal groups with three different injection times: 3d before PVR induction, during induction, and 7d afterwards (the PW3B, PW, and PW7A groups, respectively). The left eyes of all 42 rabbits were injected with WOR without PVR induction. Another 14 rabbits were randomly selected and injected with 5 mmol/L LiCl (Sigma L9650; St Louis, MO, USA), a pharmacological GSK3β inhibitor, in their right eyes at the same time as PVR induction (the PL group). Their left eyes were injected with LiCl without PVR induction. The remaining 16 rabbits were injected intravitreously with BSS (0.1 mL) in their right eyes, and their left eyes are used as uninjected controls. Note that all rabbits maintained normal intraocular pressure after intravitreal treatment. Clinical observations with an indirect ophthalmoscope were performed 1, 7, 14, 21, and 28d after PVR induction. At the same time points, vitreous and retinal samples were extracted for study. Western Blot Analysis To detect GSK3β, phosphorylated (p)-GSK3β, β-catenin, α-smooth muscle actin (α-SMA), vimentin, E-cadherin, samples were homogenized in 100 µL of ice-cold radio-immunoprecipitation assay (RIPA) buffer supplemented with the proteinase inhibitor phenylmethanesulfonyl fluoride (PMSF 100 mmol/L). Retina homogenates (40 µg of protein) were then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. After blocking nonspecific sites with 5% bovine serum albumin, the membranes were probed with the following primary antibodies: α-SMA (ab7817, Abcam, Cambridge, MA, USA), vimentin (sc-6260, Santa Cruz, Dallas, TX, USA), E-cadherin (ab6528, Abcam, Cambridge, MA, USA), Akt (cst 9271, New England Biolabs), p-Akt Ser473 (cst 9271, New England Biolabs ), GSK3β (sc-7291, Santa Cruz, Dallas, TX, USA), p-GSK3β Ser9 (sc-373800, Santa Cruz, Dallas, TX, USA), and β-catenin (sc-7963, Santa Cruz, Dallas, TX, USA) and detected with anti-mouse or anti-rabbit secondary antibodies conjugated to horseradish peroxidase (HRP; Jackson Immuno Research Laboratories) for 1h each. Bands were visualized using Amersham Imager 600 system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Analyses of the relative protein levels were evaluated by Image J software (NIH). Nuclear Magnetic Resonance Spectroscopy For metabolomics analysis by nuclear magnetic resonance (NMR), the vitreous fluid was collected and stored immediately at -80℃. The samples were dissolved in 600 μL of phosphate buffer (0.2 mol/L Na 2 HPO 4 /0.2 mol/L NaH 2 PO 4 , pH 7.4), and then centrifuged at 11 000×g for 10min at 4℃. Aliquots of the supernatant (500 μL) were transferred to 5 mm NMR tubes, and 50 μL of D 2 O was added for NMR measurements.
1 D proton spectra were recorded using the water-suppressed Carr-Purcell-
A fixed total spin-spin relaxation delay 2 nτ of 120ms was used to attenuate the broad NMR signals of slowly tumbling molecules with short T 2 relaxation times and to retain signals of low-molecular weight compounds. All 1 H NMR spectra were acquired by a Bruker AVANCE III NMR spectrometer, operated at 600.18 MHz for 1h. Spectra were obtained using the pulse sequence (RD-90-t1-90-tm-90-ACQ). Measurements for all samples were performed at 25℃ . Clinical Observation Examinations using indirect ophthalmoscopy, ocular fundus imaging, and B-scan ultrasonography were performed 28d after PVR induction. PVR was graded from 0 to 5, according to the Fastenberg classification [12] . Histology and Immunohistochemistry Rabbits were sacrificed and their eyeballs were enucleated and fixed in 4% formaldehyde +1.5% glutaraldehyde for at least 73h. The eyeballs were then embedded in paraffin. A segment including the PVR scars was selected, and cross-sectioned to 5 μm thickness. The retina sections were stained with hematoxylin and eosin (H&E). For immunohistochemical analysis, sections were incubated with mouse anti-vimentin antibodies (sc-6260, Santa Cruz, Dallas, TX, USA) at 4℃ overnight. After washing the slides three times, sections were labeled with HRPconjugated sheep anti-mouse IgG for 50min, followed by staining with 3,3'-diaminobenzidine (Beyotime; brown). Safety Evaluation The potential retinal toxicity of WOR and LiCl was evaluated by TUNEL assay and electroretinogram (ERG). Moreover, possible toxicity was examined daily by indirect ophthalmoscopy. Animals receiving intravitreous WOR or LiCl were examined by ERG 28 d after injection, and then enucleated for TUNEL analysis.
TdT-mediated dUTP Nick-end Labeling Assay
To examine the toxicity of WOR and LiCl, paraffin-embedded retinal tissue sections were deparaffinized, rehydrated, fixed with 4% paraformaldehyde for 15min at 4℃, and subjected to enzymatic digestion with proteinase K for 25min at room temperature. Induction of apoptosis was detected using the TUNEL Assay Kit (Roche 11684817910), according to the manufacturer's instructions. Electroretinogram To evaluate the severity of PVR and toxicity of WOR and LiCl, ERG were performed 1d before the injection and 7 and 28d after. The pupils of the rabbits' eyes were dilated with 5% tropicamide. The rabbits were then placed in a dark room for 30min for dark adaption. Rabbits were then anesthetized, and corneal contact lens electrodes were placed on the corneal surfaces over a layer of 1% methylcellulose gel. All these procedures were performed in dim red light. Standard white flash stimulation of the retina was performed in a scotopic background and the scotopic 0 dB ERGs were recorded. To minimize variability, the ratios of the scotopic b-wave amplitudes of the treated eyes compared to control or pre-injected eyes were used as indices of retinal function.
Statistical Analysis
All results are expressed as means± standard errors of the mean (SEM). The statistical significance among multiple groups was determined by analysis of variance; P<0.05 was considered statistically significant. All experiments were performed at least three times.
RESULTS B-scan Examination and Fundus Imaging
We also acquired B-scans 28d after PVR induction, and noted folding of the detached retina in the PVR and PL groups. However, in the WOR-treated groups, obvious funicular echo was not observed. Similar to fundus imaging, this demonstrated that the PI3K inhibitor could relieve the severity of PVR (Figure 1 ). And we also performed indirect ophthalmoscopic examinations and acquired fundus images 28d after the injection to look for evidence of traction and RD. We observed detachment of both medullary wings with significant vitreous traction in the PVR group. Additionally, the PL group displayed severe vessel distortion and blurry optic nerves. By contrast, proliferation was significantly inhibited in the WOR-treated groups (Figure 2 ). Electroretinogram Evaluation ERGs were obtained the day before the injection and 1, 7, and 28d after injection to evaluate retinal function. To minimize variability, the ratios of the B-wave amplitudes of the WOR-injected and LiCl-injected eyes to those of pre-injection eyes were used as indices of retinal function. As shown in Figure 3 , compared with the control and BSS groups, the B-wave ratios of the PW3B, PW, PW7A, and PL groups all decreased after 1, 7, and 28d. In the PL group, the B-wave ratio decreased significantly to 0.35, on day 28 compared to the control group, while the PVR group ratio was 1.11. The ratios of the PW3B, PW, and PW7A groups were all between the control and PVR groups. Down-regulation of the GSK3β and Activation of the Signaling Pathways after PVR Induction Total Akt levels were stable in all groups 7, 14, and 28d after injection of RPE cells. However, compared to the control and BSSinjection groups, the PVR induction group revealed significant time-dependent increases in β-catenin, p-Akt (Ser473), and p-GSK3β (Ser9). Meanwhile, there was a decrease in total GSK3β demonstrated in the PVR group (Figure 4) . These results suggest that the GSK3β were down-regulated during PVR induction. Morever, PI3K/Akt and Wnt/β-catenin signaling pathways are involved in PVR process.
GSK3β inhibits epithelial-mesenchymal transition
Epithelial-mesenchymal Transition after Experimental
Proliferative Vitreoretinopathy Induction After intravitreal injection of RPE cells, EMT was measured based on changes in protein expression. Retinas were screened by Western blot analysis to examine the expression of the epithelial marker E-cadherin, and the mesenchymal markers α-SMA and vimentin. E-cadherin was downregulated 7, 14, and 28d after PVR induction, while α-SMA and vimentin were significantly upregulated ( Figure 5 ).
Effects of Wortmannin and LiCl on the GSK3β Expression and Signaling Pathways
To further examine the mechanism underlying the effects of WOR, p-Akt, p-GSK3β, GSK3β, and β-catenin were examined by Western blot ( Figure 6 ). As expected, WOR treatment increased the expression of total GSK3β and abrogated the observed increases in β-catenin, p-Akt (Ser473), and p-GSK3β (Ser9) in the PVR group. LiCl treatment caused the opposite effect compared with WOR treatment. As a conclusion, the WOR treatment effectively caused activation of GSK3β and inhibited the activity of the PI3K/Akt and Wnt/β-catenin pathways.
Suppression of EMT in Experimental Proliferative
Vitreoretinopathy by Injection of Wortmannin To further evaluate the role of GSK3β in PVR, intravitreal injection with either WOR or LiCl was performed alongside RPE cell injection. Then, α-SMA, vimentin, and E-cadherin protein levels were assessed by Western blot. As shown in (Figure 7 ) in the WOR-treated group, the expression of α-SMA and vimentin was markedly decreased and the expression of E-cadherin was increased compared with the PVR and PL groups. Conversely, EMT was enhanced by inhibition of GSK3β. Immunohistochemical Analysis By immunohistochemistry, the PVR group expressed significantly more vimentin than the control group at 28d (Figure 8 ). Consistent with the Western blot results, the analysis revealed that the WOR-treated groups (PW3B, PW, and PW7A) expressed less vimentin than the PVR and PL groups.
Wortmannin and LiCl Toxicity
The toxicity of intravitreal injection of WOR and LiCl was examined by TUNEL assay ( Figure 9A ) and ERG ( Figure 9B ) during the 28d observation period. The TUNEL assay showed no evidence of apoptosis, and in ERG examination, WOR and LiCl did not affect the amplitudes of each waveform. No evidence of toxicity was found in the rabbit retina.
Multivariate Analysis of 1 H NMR Spectra of Vitreous
Metabolites The 1 H-NMR spectra of vitreous samples were recorded to exploit quantitative metabolic information and then subjected to multivariate data analysis. An unsupervised pattern recognition method, principal component analysis (PCA) ( Figure 10A , 10E, 10I, 10M, and 10Q), was first performed to explore the metabolic profiles differences among groups. Then the supervised clustering analysis of partial least squares discriminant analysis (PLS-DA) ( Figure 10B , 10F, 10J, 10N and 10R) was conducted to enhance the separations in the PCA. The parameters of Q2 (cum) and R2X (cum) were computed to test the validity of the models, and the results indicated that the PLS-DA model was reliable and suitable for metabolomics analysis. Moreover, orthogonal partial least squares discriminant analysis (OPLS-DA) was employed to modify the PLS-DA method. Those metabolites with the absolute value of r greater than 0.576, VIP value bigger than 1, and/or the P values obtained from Wilcoxon test exceeding 0.05 were used to identify variables that were responsible for the discrimination of groups. This analysis indicated a clear separation between each group in the determination of metabolic differences ( Figure 10C, 10G, 10K, 10O and 10S) . Heat plots between the groups are presented in Figure 10D , 10H, 10L, 10P, and 10T, and these dendrograms show the presence of different subclusters with different numbers of metabolites. Lastly, in order to explore the metabolic profile differences among the groups, a PCA plot with all groups ( Figure 11A ) and batch analysis plot ( Figure 11B ) were generated. Biomarker Identification The average changes of metabolites between groups were calculated by using the normalized integral, i.e. (C A -C B )/C B , where C A and C B embody the mean metabolite integrals of two groups. A list of discriminative metabolites is provided in Table 1 , which showed an increase in glycine, valine, lysine, and branched-chain amino acids in PVR group compared with the control group. Meanwhile the WOR treatment decrease these amino acids compared with PVR group. DISCUSSION Our results suggest that the severity of EMT can be attenuated by upregulating the expression of GSK3β, which blocks the Wnt/β-catenin and PI3K/Akt pathways, and indicate that GSK3β could be a potential clinical target in the treatment of PVR.
GSK3β inhibits epithelial-mesenchymal transition
We found that GSK3β expression was significantly reduced during the development of experimental PVR. To further clarify the function of GSK3β during PVR progression, GSK3β was activated and inhibited, respectively, by intravitreal injection of WOR or LiCl. Moreover, WOR was injected at three different times: 3d before induction, during induction, and 7d afterwards (in the PW3B, PW, and PW7A groups). The results showed that upregulating the expression of GSK3β in three different times all have inhibitory EMT effects, indicating the potential value of targeting GSK3β in clinical applications. Furthermore, we conducted metabolomic analysis to verify our conclusion. Metabolomics can analyze all metabolite changes from complete biological systems rather than individual cells, allowing assessment of a variety of metabolic pathways [13] .
Our 1 H-NMR analyses revealed increases in glycine, valine, lysine, and branched-chain amino acids (BCAAs; Table 1) , contrary to previous studies [14] . This is mostly due to the ubiquitin-proteasome pathway (UPP)-mediated degradation of abundant vitreous proteins. Experimental PVR progresses with increased proliferation, inflammation, oxidation, and nutrient consumption [15] [16] . With biochemical adaptation, the degradation of multiple vitreous proteins is aggravated, providing adequate amino acids for gluconeogenesis, new protein synthesis, and energy production. The increased turnover and degradation of proteins is also observed in uremia and patients with cancer cachexia [17] [18] . Our results demonstrate that compared with the PVR and PL groups, the metabolite profiles of the WOR-treated groups were closer to the control group. While the PL group presented more serious degradation of proteins in comparison with the PVR group. The metabolomics analysis demonstrates that GSK3β regulation can significantly affect EMT development, and that after GSK3β stimulation, the metabolite changes are similar to the control group.
To clarify how GSK3β plays its role in inhibiting EMT during PVR, we assessed the activation of Wnt/β-catenin and PI3K/ Akt pathways. As the critical and canonical Wnt pathway, the Wnt/β-catenin pathway participates in cell proliferation, differentiation, and various biological processes [19] [20] . GSK3β is the most important kinase and negative regulatory factor in the Wnt signaling pathway [21] . Inhibition of GSK3β leads to the accumulation of β-catenin, which activates the Wnt/ β-catenin pathway [22] [23] . The PI3K/Akt pathway is associated with cell transformation, migration, adhesion, transcription, proliferation, metabolism, and the development of human cancer [24] [25] . Notably, we found that β-catenin and p-Akt were increased during PVR development, while activation of GSK3β markedly prevented the accumulation of β-catenin and p-Akt and attenuated EMT. This demonstrates that GSK3β could alleviate the severity of EMT by regulating the Wnt/ β-catenin and PI3K/Akt pathways. Based on this, we propose that traumatic PVR leads to the activation of RPE cells, macrophages and glial cells, which downregulate GSK3β, activating the Wnt/β-catenin and PI3K/Akt signaling pathways, and leading to further fibroblast proliferation, metabolomic changes, collagen synthesis, and EMT development. Certainly, how macrophages and glial cells downregulate GSK3β remains to be investigated in a future study.
There are a few limitations to this study. Firstly, the fundamental differences between rabbits and humans must be acknowledged. Secondly, to better understand the underlying mechanism causing PVR, the establishment of WOR treatment time points should be more precise and the sample size for all the groups should be increased. Lastly, our metabolomic analysis was limited to the 28d time point, without analysis of acute and long-term chronic metabolomic changes, which also warrant further study. However, our study has demonstrated that GSK3β inhibits EMT in experimental PVR by regulating the Wnt/β-catenin and PI3K/Akt pathways. These results support our hypothesis and provide new evidence supporting the clinical targeting of these signaling pathways.
In conclusion, our study has demonstrated that GSK3β could inhibit EMT in experimental PVR by regulating the Wnt/ β-catenin and PI3K/Akt pathways. Thus, these results may provide a new promising therapeutic strategy for PVR disease. 
